File: '\\swfile\EmailIn\20251119 143838 Attachment MUSL - News re Corrections to MD&A.docx'

Promino Nutritional Sciences Inc. Announces

Filing Of Corrective Disclosure Pursuant To OSC Review

BURLINGTON, ON - November 19, 2025 - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") announces that, further to review by the Ontario Securities Commission ("OSC") of the Company's disclosure and a subsequent request from OSC staff in connection therewith, the Company has made corrective disclosure with respect to its annual management's discussion and analysis for the fiscal year ended December 31, 2024 (the "MD&A") and further filed its statement of executive compensation for the year ended December 31, 2024.

Corrective disclosure was requested by OSC staff in connection with the Company's application to revoke the failure-to-file cease trade order issued by the OSC on May 7, 2025. The corrective disclosure addresses various deficiencies, including:

Updated corporate governance disclosures as required by Form 58-101F2 Corporate Governance Disclosure (Venture Issuers);

Updated audit committee disclosures required by Form 52-110F2 Disclosure by Venture Issuers;

Enhanced disclosures surrounding the Company's related party transactions; and

Explanations of period-over-period financial variances.

For the purpose of making corrective disclosure, and in accordance with OSC Staff Notice 51-711 (Revised) - Refilings and Corrections of Errors ("SN 51-711"), the Company has filed the revised version of the MD&A on the Company's profile on SEDAR+ (www.sedarplus.com) providing additional details and clarifications with respect to the Company's enhanced related party transactions, updated corporate governance and audit committee disclosure and further explanations of period-over-period financial variances.

As a result, the Company was placed on the Errors and Refilings List in accordance with SN 51-711 and the Company will be noted on the list for a period of three years from the date of the filings noted above.

About Promino

Promino is an innovative and research driven Canadian nutraceutical company specializing in the development of science-based products for the global consumer packaged goods market, with a portfolio focused specifically on muscle health. Promino's lead product, Rejuvenate Muscle Health(TM) now benefits from a new formulation that aims to assist in the building, rebuilding, restoration and rejuvenation of natural muscle mass. Promino also offers Promino(TM), an elite performance supplement for both professional and amateur athletes to accelerate muscle recovery, build strength and accelerate recovery from injury. Promino was founded in 2015 and is located in Burlington, Ontario.

For more information about Rejuvenate Muscle(TM) Activator and where to purchase, visit www.rejuvenatemuscle.com.

To learn more about Promino, visit www.drinkpromino.com.

Forward-Looking Statements

This news release contains forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact, included in this news release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further information about Promino:

Vito Sanzone, CEO, vsanzone@drinkpromino.com, 289-348-1970 ext. 222

Marc Charbin, Investor Relations, marc.charbin@loderockadvisors.com, 416-467-5229